In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...

Inc. (NASDAQ:BLUE – Get Free Report) was the recipient of unusually large options trading on Friday. Stock investors purchased 1,893 put options on the stock. This is an increase of 28% compared to ...

We recently published a list of 10 VLEO Technology Stocks and Startups to Watch in 2025. In this article, we are going to ...

Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...

The Laguna Beach Fire Department started work on a new fuel modification zone on Wednesday, Feb. 19. Called Fuel Modification ...

Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.

Penny and Fritz Brandau, members of the Black River Audubon Society and the Ohio Bluebird Society, will give a presentation ...

A paper published in The Lancet showed that four out of four young children with Leber congenital amaurosis 4 retinal dystrophy due to a genetic deficiency of Aryl-hydrocarbon-interacting protein-like ...

Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital ...

Bluebird Bio has commercialized three gene therapy products, including one of the first for sickle cell disease, but would soon run out of cash.

The pioneering gene therapy developer will be acquired by investment firms Carlyle Group and SK Capital for a fraction of ...

The Carlyle Group and SK Capital Partners have agreed to acquire bluebird bio, Inc, a Somerville, Massachusetts-based gene therapy firm, in a take-private deal. According to terms of the agreement, ...